Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Recruiting now · Phase 1

Conditions studied: Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia

In brief

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.

Key facts

Study ID

NCT06451770

Run by

Verve Therapeutics, Inc.

People needed

36

Starts

2024-10-30

Expected to finish

2027-12-01

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Refractory hypercholesterolemia
• Refractory hypertriglyceridemia

You may not qualify if…

• Active or history of chronic liver disease
• Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
• Clinically significant or abnormal laboratory values as defined by the protocol

Where it is running

• Clinical Study Center — Clearwater, Florida, United States (enrolling)
• Clinical Study Center — Miami Lakes, Florida, United States (enrolling)
• Clinical Study Center — Port Orange, Florida, United States (enrolling)
• Clinical Study Center — New York, New York, United States (enrolling)
• Clinical Study Center — Adelaide, Australia (enrolling)
• Clinical Study Center — Melbourne, Australia (enrolling)
• Clinical Study Center — Chicoutimi, Canada (enrolling)
• Clinical Study Center — Montreal, Canada (enrolling)
• Clinical Study Center — Toronto, Canada (enrolling)
• Clinical Study Center — Amsterdam, Netherlands (enrolling)
• Clinical Study Center — Cape Town, South Africa (enrolling)
• Clinical Study Center — Johannesburg, South Africa (enrolling)
• Clinical Study Center — Liverpool, United Kingdom (enrolling)
• Clinical Study Center — London, United Kingdom (enrolling)
• Clinical Study Center 2 — Manchester, United Kingdom (enrolling)
• Clinical Study Center — Manchester, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.